Lynne Melchior, NP
Nurse Practitioner · Evansville, INNPI 1811232481
Payments from drug & device makers
Across 218 payments — averaging $17.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$490
- Insulet Corporation$471
- Tandem Diabetes Care, Inc.$460
- Lilly USA, LLC$445
- Xeris Pharmaceuticals, Inc.$292
- Novartis$168
- plus $2K from 26 others
What the payments were for
- Food & beverage$3,902100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 33 | $490 |
| Insulet Corporation | 26 | $471 |
| Tandem Diabetes Care, Inc. | 19 | $460 |
| Lilly USA, LLC | 24 | $445 |
| Xeris Pharmaceuticals, Inc. | 14 | $292 |
| Novartis | 11 | $168 |
| Amryt Pharma Holdings Ltd | 9 | $163 |
| Amgen | 9 | $159 |
| Boehringer Ingelheim | 9 | $121 |
| AbbVie | 7 | $99 |
| BETA Bionics, Inc. | 5 | $98 |
| Sanofi-aventis U.S. LLC | 6 | $96 |
| AstraZeneca(2 entities) | 5 | $79 |
| Medtronic | 5 | $79 |
| Ultragenyx Pharmaceutical Inc. | 3 | $77 |
| Abbott | 4 | $76 |
| Kyowa Kirin, Inc. | 3 | $64 |
| Dexcom, Inc. | 4 | $63 |
| Amneal Pharmaceuticals LLC | 3 | $53 |
| Corcept Therapeutics | 3 | $50 |
| Amarin Pharma, Inc. | 2 | $40 |
| Ascendis Pharma Endocrinology Inc | 2 | $39 |
| Ascensia Diabetes Care US Inc. | 2 | $37 |
| Neurocrine Biosciences, Inc. | 2 | $37 |
| Cequr Corporation | 1 | $32 |
| Chiesi USA, Inc. | 1 | $21 |
| Bayer | 1 | $20 |
| Avion Pharmaceuticals | 1 | $20 |
| Verity Pharmaceuticals Inc. | 1 | $20 |
| Radius Health, Inc. | 1 | $17 |
| Rhythm Pharmaceuticals, Inc. | 1 | $17 |
| Zealand Pharma US, Inc. | 1 | $15 |
How this compares
$3,916 in reported general payments places this provider in the 90th percentile of 2,724 nurse practitioner providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 349 | $451,208 |
| OzempicSemaglutide | 247 | $388,792 |
| JardianceEmpagliflozin | 143 | $170,407 |
| Tresiba Flextouch U-100Insulin Degludec | 114 | $105,076 |
| Tresiba Flextouch U-200Insulin Degludec | 58 | $76,437 |
| TrulicityDulaglutide | 39 | $66,181 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 30 | $58,095 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 54 | $56,765 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 13 | $36,084 |
| Novolog FlexpenInsulin Aspart | 81 | $35,129 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $34,419 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $33,559 |
| FarxigaDapagliflozin Propanediol | 24 | $31,769 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 171 | $27,328 |
| Humalog Kwikpen U-100Insulin Lispro | 51 | $18,743 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $445 | $526,518422 claims |
| Novo NordiskOzempic | $490 | $388,792247 claims |
| Boehringer IngelheimJardiance, Trijardy Xr | $121 | $177,912155 claims |
| AstraZenecaFarxiga | $79 | $31,76924 claims |
| AbbVieSynthroid, Armour Thyroid | $99 | $7,52685 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $53 | $2,766297 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 nurse practitioner providers in Indiana.
Other nurse practitioner in Evansville
- Stacey RickettsEvansville$18K
- Helen EvansEvansville$9K
- Kirk AshburnEvansville$9K
- Zhuang SantacanaEvansville$9K
- Brittney PhippsEvansville$9K
- Kristi OrbaughIndianapolis$1.3M
- Kimberly EadsPlainfield$302K
- Sean GoddardFort Wayne$180K
- Kacy RogersIndianapolis$77K
- Kristine TaylorFort Wayne$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.